JP2022513456A5 - - Google Patents

Info

Publication number
JP2022513456A5
JP2022513456A5 JP2021533367A JP2021533367A JP2022513456A5 JP 2022513456 A5 JP2022513456 A5 JP 2022513456A5 JP 2021533367 A JP2021533367 A JP 2021533367A JP 2021533367 A JP2021533367 A JP 2021533367A JP 2022513456 A5 JP2022513456 A5 JP 2022513456A5
Authority
JP
Japan
Prior art keywords
viral vector
recombinant viral
vector according
sequence
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021533367A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022513456A (ja
JP7788855B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/065718 external-priority patent/WO2020123645A1/en
Publication of JP2022513456A publication Critical patent/JP2022513456A/ja
Publication of JP2022513456A5 publication Critical patent/JP2022513456A5/ja
Application granted granted Critical
Publication of JP7788855B2 publication Critical patent/JP7788855B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021533367A 2018-12-12 2019-12-11 筋ジストロフィーの治療のための併用療法 Active JP7788855B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862778646P 2018-12-12 2018-12-12
US62/778,646 2018-12-12
PCT/US2019/065718 WO2020123645A1 (en) 2018-12-12 2019-12-11 Combination therapy for treating muscular dystrophy

Publications (3)

Publication Number Publication Date
JP2022513456A JP2022513456A (ja) 2022-02-08
JP2022513456A5 true JP2022513456A5 (cg-RX-API-DMAC7.html) 2022-12-20
JP7788855B2 JP7788855B2 (ja) 2025-12-19

Family

ID=71076668

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021533367A Active JP7788855B2 (ja) 2018-12-12 2019-12-11 筋ジストロフィーの治療のための併用療法

Country Status (9)

Country Link
US (1) US20220031865A1 (cg-RX-API-DMAC7.html)
EP (1) EP3893940A4 (cg-RX-API-DMAC7.html)
JP (1) JP7788855B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210124969A (cg-RX-API-DMAC7.html)
CN (1) CN113646004A (cg-RX-API-DMAC7.html)
AU (1) AU2019395388A1 (cg-RX-API-DMAC7.html)
CA (1) CA3123003A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202105873SA (cg-RX-API-DMAC7.html)
WO (1) WO2020123645A1 (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108463211B (zh) 2015-11-16 2022-09-27 全国儿童医院研究所 用于治疗肌联蛋白类肌病和其它肌联蛋白病变的材料和方法
US11338045B2 (en) 2017-03-17 2022-05-24 Newcastle University Adeno-associated virus vector delivery of a fragment of micro-dystrophin to treat muscular dystrophy
AU2019216257B2 (en) 2018-01-31 2025-11-20 Research Institute At Nationwide Children's Hospital Gene therapy for limb-girdle muscular dystrophy type 2C
IL324506A (en) 2018-06-18 2026-01-01 Res Inst Nationwide Childrens Hospital Adeno-associated virus vector for delivery of muscle-specific microdystrophin for the treatment of muscular dystrophy
IL279789B2 (en) 2018-06-29 2026-04-01 Res Inst Nationwide Childrens Hospital Recombinant adeno-associated virus products and methods for treating limb girdle muscular dystrophy 2A
KR20210133242A (ko) 2019-02-26 2021-11-05 더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 B-사르코글리칸의 아데노 관련 바이러스 벡터 전달 및 근이영양증의 치료
CA3150964A1 (en) 2019-08-21 2021-02-25 Research Institute At Nationwide Children's Hospital Adeno-associated virus vector delivery of alpha-sarcoglycan and the treatment of muscular dystrophy
CN115279421A (zh) * 2020-01-10 2022-11-01 坚固生物科技公司 用于联合疗法的病毒载体
EP4164668A1 (en) 2020-06-15 2023-04-19 Research Institute at Nationwide Children's Hospital Adeno-associated virus vector delivery for muscular dystrophies
EP4086276A1 (en) 2021-05-03 2022-11-09 Université d'Aix-Marseille Composition for treating dysferlinopathy
EP4108263A3 (en) 2021-06-02 2023-03-22 Research Institute at Nationwide Children's Hospital Recombinant adeno-associated virus products and methods for treating limb girdle muscular dystrophy 2a
TW202308664A (zh) * 2021-07-08 2023-03-01 日商日本新藥股份有限公司 腎毒性減輕劑
US20240390522A1 (en) * 2021-09-28 2024-11-28 University Of Florida Research Foundation, Incorporated Gene therapy for duchenne muscular dystrophy
US12285497B2 (en) 2021-10-15 2025-04-29 Research Institute At Nationwide Children's Hospital Self-complementary adeno-associated virus vector and its use in treatment of muscular dystrophy
US20250215426A1 (en) * 2022-04-05 2025-07-03 Astellas Gene Therapies, Inc. Compositions and methods for the treatment of muscular dystrophies
WO2023225592A2 (en) * 2022-05-18 2023-11-23 Inadcure Foundation Inc. Gene therapies for treatment of infantile neuroaxonal dystrophy
AU2023356650A1 (en) * 2022-10-06 2025-04-17 Solid Biosciences Inc. Dual transfection vector
CN117959464A (zh) * 2022-10-27 2024-05-03 苏州新芽基因生物技术有限公司 用于疾病治疗的基因编辑器和抗纤维化抑制剂的核酸药物组合物
CN116218849B (zh) * 2023-01-18 2024-01-23 昆明理工大学 针对utrophin激活治疗杜氏肌营养不良的sgRNA和应用
JP2026516715A (ja) * 2023-04-18 2026-05-26 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル 肢帯型筋ジストロフィーr9及び先天性筋ジストロフィー1cを治療するための遺伝子療法
WO2024229164A2 (en) * 2023-05-03 2024-11-07 Voyager Therapeutics, Inc. Compositions and methods for the treatment of disorders related to dystrophia myotonica protein kinase
CN116926125B (zh) * 2023-09-07 2024-06-11 昆明理工大学 一种抑制炎症与基因编辑同时进行的基因载体
WO2025085731A1 (en) * 2023-10-18 2025-04-24 Children's National Medical Center TRANSFORMING GROWTH FACTOR ß (TGF-ß) OLIGONUCLEOTIDE COMBINATION THERAPY FOR TREATING MUSCULOSKELETAL DISEASES
WO2026090457A1 (en) * 2024-10-25 2026-04-30 Stark Therapeutics Corporation Methods of treatment of metabolic diseases

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8314290B2 (en) * 2004-12-21 2012-11-20 Monsanto Technology Llc Temporal regulation of gene expression by MicroRNAs
CN102311973A (zh) * 2010-07-05 2012-01-11 北京五加和分子医学研究所有限公司 一种新型miRNA和编码蛋白基因共表达载体
JP2014103905A (ja) * 2012-11-28 2014-06-09 Tokai Univ 標的遺伝子のノックダウン方法およびそのためのRNAi用発現ベクター
AU2015208247B2 (en) * 2014-01-21 2021-05-27 Universiteit Gent Muscle-specific nucleic acid regulatory elements and methods and use thereof
KR102244434B1 (ko) * 2014-08-11 2021-04-23 삼성전자주식회사 재조합 벡터 및 이를 이용한 목적 폴리펩타이드의 생산 방법
WO2016115543A2 (en) * 2015-01-16 2016-07-21 University Of Washington Novel micro-dystrophins and related methods of use
US10543260B2 (en) * 2015-07-22 2020-01-28 The Board Of Trustees Of The Leland Stanford Junior University Replacement gene tolerizing vectors and methods of use thereof
US12214054B2 (en) * 2015-11-30 2025-02-04 Duke University Therapeutic targets for the correction of the human dystrophin gene by gene editing and methods of use
WO2017181011A1 (en) * 2016-04-15 2017-10-19 Research Institute At Nationwide Children's Hospital Adeno-associated virus vector delivery of microrna-29 to treat muscular dystrophy
BR112019015081A2 (pt) * 2017-01-23 2020-03-10 Rutgers, The State University Of New Jersey Composições para reduzir a expressão da sarcolipina e prevenir e tratar a distrofia muscular e a cardiomiopatia e os métodos de utilização
WO2018200419A1 (en) 2017-04-23 2018-11-01 The Trustees Of The University Of Pennsylvania Viral vectors comprising engineered aav capsids and compositions containing the same
CA3078096A1 (en) * 2017-10-20 2018-10-19 Genethon Use of syncytin for targeting drug and gene delivery to regenerating muscle tissue

Similar Documents

Publication Publication Date Title
US20240409940A1 (en) Modified aav constructs and uses thereof
US10905776B2 (en) Isolation of novel AAV's and uses thereof
JP7788855B2 (ja) 筋ジストロフィーの治療のための併用療法
ES2732023T3 (es) Supresión del gen de la huntingtina inducida por ARNi
JP2022505381A5 (cg-RX-API-DMAC7.html)
WO2016054557A1 (en) Novel high efficiency library-identified aav vectors
JP2022516515A (ja) Rna標的化crispr-cas13bを使用するdux4 rna発現停止
JP2021534755A (ja) 筋強直性ジストロフィープロテインキナーゼの発現を抑制および/またはdmpk遺伝子の3’非翻訳領域におけるトリヌクレオチドリピート伸長に干渉するための組換えウイルス産物および方法
WO2020142714A1 (en) Aav expression cassette and aav vectors comprising the same
JP2022553573A5 (cg-RX-API-DMAC7.html)
JP2020535804A5 (cg-RX-API-DMAC7.html)
EP3837374A1 (en) Combination therapy for spinal muscular atrophy
JP2024519175A (ja) 新規なデュアルヘルパープラスミド
JP2026511976A (ja) Dm-1筋強直性ジストロフィーの標的遺伝子療法
WO2023220719A2 (en) Method for treatment of myotonic dystrophy combining protein expression and rna interference vector delivery with tissue detargeting
JP2017506638A (ja) 肝傷害を治療するための組成物及び方法
JP2025509262A5 (cg-RX-API-DMAC7.html)
JP2025512709A5 (cg-RX-API-DMAC7.html)
JP2024522216A (ja) インフラマソーム関連疾患または障害を治療するためのmirna-485阻害剤の使用
RU2742435C2 (ru) Композиции промоторов
JP2022508835A5 (cg-RX-API-DMAC7.html)
US20250320256A1 (en) Aav5 capsid with non-canonical amino acid incorporation and uses thereof
RU2716999C1 (ru) Способ получения рекомбинантных аденоассоциированных вирусов для использования в генной терапии
KR20260007568A (ko) Mirna-484 억제제 및 이의 용도
AU2024247959A1 (en) Nucleic acid off-switches and methods and uses thereof